Skip to main content
Top
Published in: Journal of Clinical Immunology 2/2015

01-02-2015 | Original Research

Spectrum and Management of Complement Immunodeficiencies (Excluding Hereditary Angioedema) Across Europe

Authors: A. J. Turley, B. Gathmann, C. Bangs, M. Bradbury, S. Seneviratne, L. I. Gonzalez-Granado, S. Hackett, N. Kutukculer, H. Alachkar, S. Hambleton, H. Ritterbusch, P. Kralickova, L. Marodi, M. G. Seidel, G. Dueckers, J. Roesler, A. Huissoon, H. Baxendale, J. Litzman, P. D. Arkwright

Published in: Journal of Clinical Immunology | Issue 2/2015

Login to get access

Abstract

Introduction

Complement immunodeficiencies (excluding hereditary angioedema and mannose binding lectin deficiency) are rare. Published literature consists largely of case reports and small series. We collated data from 18 cities across Europe to provide an overview of primarily homozygous, rather than partial genotypes and their impact and management.

Methods

Patients were recruited through the ESID registry. Clinical and laboratory information was collected onto standardized forms and analyzed using SPSS software.

Results

Seventy-seven patients aged 1 to 68 years were identified. 44 % presented in their first decade of life. 29 % had C2 deficiency, defects in 11 other complement factors were found. 50 (65 %) had serious invasive infections. 61 % of Neisseria meningitidis infections occurred in patients with terminal pathway defects, while 74 % of Streptococcus pneumoniae infections occurred in patients with classical pathway defects (p < 0.001). Physicians in the UK were more likely to prescribe antibiotic prophylaxis than colleagues on the Continent for patients with classical pathway defects. After diagnosis, 16 % of patients suffered serious bacterial infections. Age of the patient and use of prophylactic antibiotics were not associated with subsequent infection risk. Inflammatory/autoimmune diseases were not seen in patients with terminal pathway, but in one third of patients classical and alternative pathway defects.

Conclusion

The clinical phenotypes of specific complement immunodeficiencies vary considerably both in terms of the predominant bacterial pathogen, and the risk and type of auto-inflammatory disease. Appreciation of these phenotypic differences should help both immunologists and other specialists in their diagnosis and management of these rare and complex patients.
Literature
1.
go back to reference Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014;61:110–7.CrossRefPubMed Grumach AS, Kirschfink M. Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach. Mol Immunol. 2014;61:110–7.CrossRefPubMed
2.
go back to reference Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014;34:478–90.CrossRefPubMed Aghamohammadi A, Mohammadinejad P, Abolhassani H, Mirminachi B, Movahedi M, Gharagozlou M, et al. Primary immunodeficiency disorders in Iran: update and new insights from the third report of the national registry. J Clin Immunol. 2014;34:478–90.CrossRefPubMed
3.
go back to reference Zelazko M, Carneiro-Sampaio M, de Luigi Cornejo M, de Olarte Garcia D, Porras Madrigal O, Berron Perez R, et al. Primary immunodeficiency diseases in Latin America: first report from eight countries participating in the LAGID. Latin American Group for Primary Immunodeficiency Diseases. J Clin Immunol. 1998;18:161–6.CrossRefPubMed Zelazko M, Carneiro-Sampaio M, de Luigi Cornejo M, de Olarte Garcia D, Porras Madrigal O, Berron Perez R, et al. Primary immunodeficiency diseases in Latin America: first report from eight countries participating in the LAGID. Latin American Group for Primary Immunodeficiency Diseases. J Clin Immunol. 1998;18:161–6.CrossRefPubMed
4.
go back to reference Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens. 2006;68:193–209.CrossRefPubMed Dommett RM, Klein N, Turner MW. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens. 2006;68:193–209.CrossRefPubMed
5.
go back to reference Khan S, Tarzi MD, Doré PC, Sewell WA, Longhurst HJ. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol. 2007;123:14–7.CrossRefPubMed Khan S, Tarzi MD, Doré PC, Sewell WA, Longhurst HJ. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol. 2007;123:14–7.CrossRefPubMed
6.
7.
go back to reference Polley MJ. Inherited c’2 deficiency in man: lack of immunochemically detectable c’2 protein in serums from deficient individuals. Science. 1968;161:1149–51.CrossRefPubMed Polley MJ. Inherited c’2 deficiency in man: lack of immunochemically detectable c’2 protein in serums from deficient individuals. Science. 1968;161:1149–51.CrossRefPubMed
8.
go back to reference Alper CA, Abramson N, Johnston RB, Jandl JH, Rosen FS. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med. 1970;282:350–4.PubMed Alper CA, Abramson N, Johnston RB, Jandl JH, Rosen FS. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med. 1970;282:350–4.PubMed
9.
go back to reference Torisu M, Sonozaki H, Inai S, Arata M. Deficiency of the fourth component of complement in man. J Immunol. 1970;104:728–37.PubMed Torisu M, Sonozaki H, Inai S, Arata M. Deficiency of the fourth component of complement in man. J Immunol. 1970;104:728–37.PubMed
10.
go back to reference Miller ME, Nilsson UR. A familial deficiency of the phagocytosis-enhancing activity of serum relates to a dysfunction of the fifth component of complement (C5). N Engl J Med. 1970;282:354–8.CrossRefPubMed Miller ME, Nilsson UR. A familial deficiency of the phagocytosis-enhancing activity of serum relates to a dysfunction of the fifth component of complement (C5). N Engl J Med. 1970;282:354–8.CrossRefPubMed
11.
go back to reference Moncada B, Day NK, Good RA, Windhorst DB. Lupus-erythematosus-like syndrome with a familial defect of complement. N Engl J Med. 1972;286:689–93.CrossRefPubMed Moncada B, Day NK, Good RA, Windhorst DB. Lupus-erythematosus-like syndrome with a familial defect of complement. N Engl J Med. 1972;286:689–93.CrossRefPubMed
12.
go back to reference Petersen BH, Lee TJ, Snyderman R, Brooks GF. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann Intern Med. 1979;90:917–20.CrossRefPubMed Petersen BH, Lee TJ, Snyderman R, Brooks GF. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency. Ann Intern Med. 1979;90:917–20.CrossRefPubMed
14.
go back to reference Gaschignard J, Levy C, Chrabieh M, Boisson B, Bost-Bru C, Dauger S, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis. 2014;59:244–51.CrossRefPubMed Gaschignard J, Levy C, Chrabieh M, Boisson B, Bost-Bru C, Dauger S, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis. 2014;59:244–51.CrossRefPubMed
16.
go back to reference Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34(5). Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34(5).
18.
go back to reference Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis–a new look at an old entity. N Engl J Med. 2012;366:1119–31.CrossRefPubMed Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis–a new look at an old entity. N Engl J Med. 2012;366:1119–31.CrossRefPubMed
19.
go back to reference Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454–64.CrossRefPubMed Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454–64.CrossRefPubMed
20.
go back to reference Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol. 2004;113:585–93.CrossRefPubMed Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol. 2004;113:585–93.CrossRefPubMed
21.
go back to reference Rodriguez-Marco A, Bradbury M, Riley P, Arkwright PD. Autoimmunity and recurrent infections in partial complement C3 immunodeficiency. Rheumatology (Oxford). 2010;49:1017–9.CrossRef Rodriguez-Marco A, Bradbury M, Riley P, Arkwright PD. Autoimmunity and recurrent infections in partial complement C3 immunodeficiency. Rheumatology (Oxford). 2010;49:1017–9.CrossRef
22.
go back to reference Arkwright PD, Riley P, Hughes SM, Alachkar H, Wynn RF. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2014;133:265–7.CrossRefPubMed Arkwright PD, Riley P, Hughes SM, Alachkar H, Wynn RF. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2014;133:265–7.CrossRefPubMed
23.
go back to reference Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004;15:787–95.CrossRefPubMed Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol. 2004;15:787–95.CrossRefPubMed
24.
go back to reference Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010;77:339–49.CrossRefPubMed Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, et al. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int. 2010;77:339–49.CrossRefPubMed
25.
go back to reference Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood. 2012;119:4182–91.CrossRefPubMedCentralPubMed Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood. 2012;119:4182–91.CrossRefPubMedCentralPubMed
26.
go back to reference Boteva L, Morris DL, Cortés-Hernández J, Martin J, Vyse TJ, Fernando MM. Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. Am J Hum Genet. 2012;90:445–56.CrossRefPubMedCentralPubMed Boteva L, Morris DL, Cortés-Hernández J, Martin J, Vyse TJ, Fernando MM. Genetically determined partial complement C4 deficiency states are not independent risk factors for SLE in UK and Spanish populations. Am J Hum Genet. 2012;90:445–56.CrossRefPubMedCentralPubMed
27.
go back to reference Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62–73.CrossRefPubMedCentralPubMed Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2013;162:62–73.CrossRefPubMedCentralPubMed
28.
go back to reference Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.CrossRefPubMed Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.CrossRefPubMed
29.
go back to reference Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med. 2012;366:1165–6.CrossRefPubMed Radhakrishnan S, Lunn A, Kirschfink M, Thorner P, Hebert D, Langlois V, et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med. 2012;366:1165–6.CrossRefPubMed
30.
go back to reference Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Käyhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine. 2003;21:4437–47.CrossRefPubMed Platonov AE, Vershinina IV, Kuijper EJ, Borrow R, Käyhty H. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine. 2003;21:4437–47.CrossRefPubMed
31.
go back to reference Gomez-Lus ML, Giménez MJ, Vázquez JA, Aguilar L, Anta L, Berrón S, et al. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination. Infection. 2003;31:51–4.CrossRefPubMed Gomez-Lus ML, Giménez MJ, Vázquez JA, Aguilar L, Anta L, Berrón S, et al. Opsonophagocytosis versus complement bactericidal killing as effectors following Neisseria meningitidis group C vaccination. Infection. 2003;31:51–4.CrossRefPubMed
32.
go back to reference Brown JS, Hussell T, Gilliland SM, Holden DW, Paton JC, Ehrenstein MR, et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A. 2002;99:16–969. Brown JS, Hussell T, Gilliland SM, Holden DW, Paton JC, Ehrenstein MR, et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A. 2002;99:16–969.
33.
go back to reference Yuste J, Sen A, Truedsson L, Jönsson G, Tay LS, Hyams C, et al. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun. 2008;76:3761–70.CrossRefPubMedCentralPubMed Yuste J, Sen A, Truedsson L, Jönsson G, Tay LS, Hyams C, et al. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun. 2008;76:3761–70.CrossRefPubMedCentralPubMed
34.
go back to reference Alba-Domínguez M, López-Lera A, Garrido S, Nozal P, González-Granado I, Melero J, et al. Complement factor I deficiency: a not so rare immune defect: characterization of new mutations and the first large gene deletion. Orphanet J Rare Dis. 2012;7:42.CrossRefPubMedCentralPubMed Alba-Domínguez M, López-Lera A, Garrido S, Nozal P, González-Granado I, Melero J, et al. Complement factor I deficiency: a not so rare immune defect: characterization of new mutations and the first large gene deletion. Orphanet J Rare Dis. 2012;7:42.CrossRefPubMedCentralPubMed
35.
go back to reference Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol. 2013;735:155–72.CrossRefPubMed Risitano AM. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol. 2013;735:155–72.CrossRefPubMed
37.
go back to reference Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices. Morbidy and Mortality weekly report. 2013; 62:2. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the advisory committee on immunization practices. Morbidy and Mortality weekly report. 2013; 62:2.
38.
go back to reference Ladhani SN, Cordery R, Mandal S, Christensen H, Campbell H, Borrow R, et al. Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(®)). J Infect. 2014;69:470–80.CrossRefPubMed Ladhani SN, Cordery R, Mandal S, Christensen H, Campbell H, Borrow R, et al. Preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using a recently-licensed, multi-component, protein-based vaccine (Bexsero(®)). J Infect. 2014;69:470–80.CrossRefPubMed
39.
go back to reference Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1:573–82.CrossRefPubMed Kuruvilla M, de la Morena MT. Antibiotic prophylaxis in primary immune deficiency disorders. J Allergy Clin Immunol Pract. 2013;1:573–82.CrossRefPubMed
40.
go back to reference Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–57.CrossRefPubMed Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V, French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–57.CrossRefPubMed
Metadata
Title
Spectrum and Management of Complement Immunodeficiencies (Excluding Hereditary Angioedema) Across Europe
Authors
A. J. Turley
B. Gathmann
C. Bangs
M. Bradbury
S. Seneviratne
L. I. Gonzalez-Granado
S. Hackett
N. Kutukculer
H. Alachkar
S. Hambleton
H. Ritterbusch
P. Kralickova
L. Marodi
M. G. Seidel
G. Dueckers
J. Roesler
A. Huissoon
H. Baxendale
J. Litzman
P. D. Arkwright
Publication date
01-02-2015
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 2/2015
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-015-0137-5

Other articles of this Issue 2/2015

Journal of Clinical Immunology 2/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.